We report the case of a t(14:18) + follicular lymphoma (FL) patient in long-term clinical remission after undergoing an allogeneic bone marrow transplantation (allo-BMT) from a human leukocyte antigen (HLA)-identical sibling donor who was the normal healthy carrier of a t(14:18) + B cell clone. Using real-time quantitative PCR (RQ-PCR) and gel electrophoresis, we document the temporal disappearance of the patient's t(14:18) + clone early post-transplant with the concomitant emergence and long-term persistence of the donor's t(14:18) + clone in the patient's peripheral blood. This report indicates that the use of PCR-based techniques to measure minimal residual disease in FL patients post-alloBMT should incorporate pretransplant screening of the donor for t(14;18). Furthermore, it suggests that healthy individuals with t(14:18) need not be excluded as donors for FL patients treated with allo-BMT. Bone Marrow Transplantation (2003) 31, 947-949.
medical genetics
Follicular lymphoma (FL) is characterized by the t(14:18) gene rearrangement, which results in bcl-2 proto-oncogene overexpression and increased tumor cell survival. 1 It is one of the most frequent subtypes of malignant lymphoma in Western countries and is generally accepted to be incurable with conventional therapy. Although many patients may achieve a complete remission with standard treatment, the median duration of these remissions is approximately 2.5 years, with a disease-free survival of only 25% at 5 years. 2 High-dose therapy with allogeneic bone marrow transplantation (alloBMT) provides hope for improving the survival of FL patients. Although long-term follow-up is pending, durable clinical remissions have been achieved in approximately 50-80% of patients treated with alloBMT at 3 years post-transplant. 3 Despite a significant improvement in remission rate, many FL patients treated with alloBMT relapse. Laboratory methods that predict which patients are destined to relapse may prove valuable in making timely treatment decisions in the post-transplant setting. Our group and others have recently shown that monitoring levels of minimal residual disease (MRD), by using real-time quantitative PCR (RQ-PCR) for t(14;18) + lymphocytes, may predict relapse in FL patients post-BMT before overt clinical relapse. 4, 5 In these studies, clinical relapse is usually preceded by a gradual increase in the quantity of t(14;18) + neoplastic lymphocytes post-BMT, while long-term clinical remission is associated with negative or stable low levels of (14;18) + lymphocytes. Distinguishing between patient and donor origin of t(14;18) + clones in these studies is confounded by the observation that approximately 23-50% of normal healthy individuals have detectable t(14;18) positive cells in their peripheral blood (PB). [6] [7] [8] In the present study, we report the case of an FL patient with neoplastic lymphocytes carrying a t(14:18) translocation who underwent an alloBMT from an human leukocyte antigen (HLA)-identical sibling, who was a normal healthy carrier of a t(14:18) translocation. Using RQ-PCR and gel electrophoresis, we document the temporal disappearance of the patient's t(14:18) + clone early post-transplant with the concomitant emergence and long-term persistence of the donor's t(14:18) + clone in the patient's PB.
Case Report
A 42-year-old woman presented in June 1992 with a 6-month history of fatigue, night sweats, weight loss and generalized lymphadenopathy. Computed tomography (CT) scans of the chest, abdomen and pelvis showed extensive bilateral axillary, mediastinal, subcarinal and pericardial lymphadenopathy. Cervical node biopsy revealed a FL, grade 1/3 (predominantly small cleaved cells) with focal diffuse areas. Bilateral bone marrow biopsies showed marrow involvement (stage 4B).
The patient initially received two cycles of vincristine, cyclophosphamide and prednisone chemotherapy with minimal response. She then was treated with seven cycles of cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Restaging after her final cycle of CHOP showed a complete resolution of chest adenopathy, but residual disease remained in the abdomen. Bone marrow biopsy was positive for lymphoma. The patient then underwent a T cell depleted alloBMT from an HLAidentical sibling donor. Conditioning was cyclophosphamide, Ara-C, methylprednisolone and total body irradiation (14 Gy). 9 The transplant was complicated by the development of moderate (Grade II) graft-versus-host disease (GVHD) of the skin at approximately 40 days post-transplant, which was treated successfully with cyclosporine and topical corticosteroids. She had no further complications. Bone marrow biopsy performed at three weeks post-transplant showed no morphological evidence of lymphoma, and CT scans performed at three months post-transplant and at all times thereafter showed no evidence of recurrent disease. VNTR studies of PB demonstrated 100% donor chimerism at one month post-transplant, which remained unchanged at all further times tested (42 years). The patient is currently alive at 49 years post-transplant with no evidence of disease. The donor also remains healthy.
In an attempt to correlate FL relapse with early molecular detection of MRD, we performed t(14;18)-specific RQ-PCR on PB samples collected from both the patient and donor pretransplant and from the patient at various times post-transplant (Table 1) The quantity of t(14;18) positive cells/total mononuclear cells was measured by RQ-PCR utilizing primers, and probes specific for t(14;18) at the major breakpoint region (MBR), as previously described. 5 The PCR products were then subjected to agarose gel electrophoresis to visualize their size (Figure 1) . Amplification of t(14;18) at the MBR was observed using DNA isolated from donor PB (Figure 1 'D'). The donor had normal blood counts as well as no evidence of lymphadenopathy, organomegaly, or any other physical symptoms, confirming him to be a normal healthy individual carrying a t(14;18) + clone. Amplification of t(14;18) at the MBR was also observed using DNA isolated from the patient's PB approximately two weeks prior to transplant (Figure 1 'pre BMT'). Of note, the exact position of the chromosomal breakpoints within the MBR differed by approximately 10-20 bp when comparing the donor and patient's t(14;18), thus allowing the two amplified products to be resolved by gel electrophoresis. In PB taken from the patient 27 days post-transplant, the patient's t(14;18) + clone was undetectable, whereas the presence of the donor's t(14;18) + clone was readily observed. In contrast, 88 days post-transplant, both the patient's and donor's t(14;18) bands were detected. However, at all subsequent time points (up to 45 years post-transplant; Figure 1 ), the only detectable t(14;18) + clone in the patient's PB was that of the donor. RQ-PCR results showed that the quantity of t(14;18) + donor lymphocytes remain stable at o0.01% of mononuclear cells over these years post-BMT (Table 1) .
Discussion
To the best of our knowledge, this is the first reported case of a t(14;18) + FL patient, who underwent an alloBMT from an HLA-identical donor having another t(14;18) + B cell clone. Utilizing RQ-PCR on DNA isolated from the patient's PB, we document the disappearance of the patient's malignant t(14;18) + clone, with the early emergence and long-term persistence of the donor's nonmalignant t(14;18) + clone post-transplant. This pattern correlates with the long-term disease-free survival observed in this patient.
This report is a clear example of why both patient and donor should be screened for t(14;18) when using PCRbased techniques to measure MRD in FL patients posttransplant. If the donor was not screened for t(14;18) in this case, the presence of t(14;18) in the patient's PB early after transplant may have been mistaken for MRD. Consequently, unnecessary treatment may have been offered. Furthermore, without knowing the precise size of the donor's t(14;18), the presence of two different t(14;18) + MBR-specific RQ-PCR was performed using 250 ng of DNA isolated from either donor or patient PB pre-and post-transplant, as previously described. clones in the patient's PB at 88 days post-transplant may have been mistaken for the emergence of a new patientderived malignant t(14;18) + clone. Since it has been reported that as many as 50% of normal healthy individuals carry t(14;18) + clone(s), we speculate that the case reported here is not an aberration, but may in fact be a common phenomenon when using PCR-based techniques to assay for t(14;18) in the allogeneic transplant setting. In a previous report using qualitative PCR, we showed that clinical remission in FL patients treated with alloBMT correlates with PCR-negative disease. 3 However, in this study PCR-positive disease did not necessarily predict clinical relapse. Since the donors were not screened, we may have been detecting t(14;18) of donor origin in these 'PCRpositive' patients, which could possibly explain long-term clinical remissions observed in this group.
This case provides further evidence suggesting that the t(14;18) + clone by itself does not necessarily impart malignant potential, even when transplanted to a host who is severely immunosuppressed and may be genetically susceptible to developing FL. Moreover, donors carrying t(14;18) may retain the ability to mediate graft-versuslymphoma, as suggested by the disappearance of the malignant t(14;18) clone in the absence of recent chemotherapy ( Figure 1 '+177 to 45years'). Given that such a large number of healthy individuals possess t(14;18) + cells, it is inferred from this case that these individuals should not necessarily be excluded as donors for FL patients undergoing alloBMT, although more cases are needed to substantiate this hypothesis. Such data can only be obtained, however, through donor screening for t(14;18).
